BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Home > article

Samsung Bioepis wins U.S. approval to sell cancer-treating biosimilar

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : January 21, 2019, 10:02 | Updated : April 3, 2019, 16:56
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Samsung Bioepis]


SEOUL -- Samsung Bioepis has won approval to sell Ontruzant, a cancer-treating biosimilar referencing Herceptin, in the United States. It was the company's first oncology biosimilar to receive approval from the U.S. Food and Drug Administration (FDA).

Samsung Bioepsis is a joint venture with Samsung BioLogics affiliated with South Korea's largest Samsung Group, and Biogen, U.S.-based pharmaceutical company Biogen. Bioepsis has been known for Imraldi, an adalimumab biosimilar referencing Humira.

Trastuzumab, sold under the brand name Herceptin, is a monoclonal antibody used to treat breast cancer developed by Swiss pharmaceutical giant Roche. Ontruzant will be distributed in the U.S. market by Merck, known as MSD, which sells the biosimilar in Europe.

"For many cancer patients in the U.S., battling cancer has not only been a health issue, but a considerable financial burden brought on by cancer treatment," Bioepis senior vice president Pak Sang-jin said in a statement. "We sincerely hope our trastuzumab biosimilar will do exactly that."



 

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Prosecutors raid stock operators office in probe into Samsungs biosimilar arm.
    Prosecutors raid stock operator's office in probe into Samsu…
  • .Samsung Bioepis demonstrates efficacy of first biosimilar for eye disease treatment.
    Samsung Bioepis demonstrates efficacy of first biosimilar fo…
  • .Samsung Bioepis partners with 3SBio to commercialize biosimilar candidates in China.
    Samsung Bioepis partners with 3SBio to commercialize biosimi…
  • .Samsung Bioepis cancer-treating biosimilar Ontruzant is available in U.S. .
    Samsung Bioepis' cancer-treating biosimilar Ontruzant is ava…
  • .Samsung Bioepis allowed to go ahead with clinical trial in China for biosimilar candidate.
    Samsung Bioepis allowed to go ahead with clinical trial in C…

Real Time Photo News

  • .KT jumps into Vietnams music streaming market with digital platform.

    KT jumps into Vietnam's music streaming market with digital platform

  • .K-pop girl band MAMAMOOs label acquires rival entertainment company.

    K-pop girl band MAMAMOO's label acquires rival entertainment company

  • .BTS agency expands U.S. business scope thru acquisition of Ithaca Holdings.

    BTS agency expands U.S. business scope thru acquisition of Ithaca Holdings

  • .CJs drama-making wing forges partnership with webcomics studio YLAB.

    CJ's drama-making wing forges partnership with webcomics studio YLAB

  • .Historical inaccuracies lead to rare withdrawal of TV series in S. Korea.

    Historical inaccuracies lead to rare withdrawal of TV series in S. Korea

Latest News

more+

  • [FOCUS] President Moon hails rollout of home-made fighter jet as 'historic milestone'
  • Researchers develop tiny wearable metasurface gas sensor for holographic visual alarms
  • Researchers discover method to mass-produce carminic acid from glucose
  • KT jumps into Vietnam's music streaming market with digital platform
  • Daewoo shipyard gets smarter with advanced digital technologies
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view